NIAID research initiatives focused exclusively or in part on antimicrobial resistance — listed by fiscal year (FY) in which awards will be made. (You can use the NIH RePORTER to retrieve details about projects funded by these initiatives.)
FY26
- 2026 NIAID DMID Omnibus Broad Agency Announcement
- Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRUs) (P01 Clinical Trial Not Allowed)
- Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP) (P01 Clinical Trial Not Allowed)
- Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed)
FY25
- Centers of Excellence for Translational Research
- 2024 NIAID Omnibus Broad Agency Announcement
- Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antibiotic-Resistant Gram-Negative Bacteria
FY24
FY23
- Host Immunity and Novel Immunization Strategies for Clostridioides difficile Infection (CDI) (U19, Clinical Trial Not Allowed)
- 2022 NIAID Omnibus Broad Agency Announcement
- Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi
- Partnerships for Rapid Diagnostics and Phenotypic Antibacterial Susceptibility Testing for Bacteremia or Hospital Acquired Pneumonia
FY22
FY21
- Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21)
- Chemistry Center for Combatting Antibiotic-Resistant Bacteria
- Combatting Antibiotic-Resistant Bacteria Interdisciplinary Research Units (U19)
- Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections and Emerging Infectious Diseases
FY20
- Leadership Group for a Clinical Research Network on Antibacterial Resistance (UM1)
- Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections and Emerging Infectious Diseases
FY19
- Centers of Excellence for Translational Research (U19)
- Partnerships for Countermeasures against Select Pathogens (R01)
- Sexually Transmitted Infections (STI) Cooperative Research Centers (U19)
FY18
- Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antimicrobial-Resistant Gram-Negative Bacteria (R01)
- Partnerships for Development of Clinically Useful Diagnostics for Antimicrobial- Resistant Bacteria
- Partnerships for the Development of Vaccines and Immunoprophylactics Targeting Mulitple Antimicrobial-Resistant Bacteria
- Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21)
- Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01)
FY17
FY16
- Development of Therapeutic Products for Biodefense and Emerging Infectious Diseases
- Partnerships for the Development of Host-Targeted Therapeutics to Limit Antibacterial Resistance
- Non-Traditional Therapeutics that Limit Antibacterial Resistance
- Systems Biology and Antibacterial Resistance
FY15
- Development of Novel Therapeutics for Select Anaerobic Protozoa
- Development of Novel Therapeutics for Select Pathogens
- Partnerships for Diagnostics to Address Antimicrobial Resistance of Select Bacterial Pathogens
- Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases
- Targeting Therapeutics Development to Relieve Bottlenecks
FY14
- Centers of Excellence for Translational Research
- Drug Target Development and Validation for Antimicrobial Resistant Pathogens
- Leadership Group for a Clinical Research Network on Antibacterial Resistance
- Partnerships for Biodefense
- Pharmacological Approaches to Evaluating Drug Regimens to Address Antimicrobial Resistance
- Sexually Transmitted Infections Cooperative Research Centers
FY13
- Development of Therapeutic Medical Countermeasures for Biodefense and Emerging Infectious Diseases
- Partnerships for Development of Therapeutics and Diagnostics for Biodefense
- Partnerships for Interventions to Treat Chronic, Persistent and Latent Infections
- Sexually Transmitted Infections Clinical Trials Group
FY12
- Chemical Approaches to Target Validation for Drug Resistant Pathogens
- Targeting Resistance in Select Gram-Negative Pathogens
FY11
FY10
- Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (R01)
- Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (SBIR)
- Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance